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ABSTRACT 
Objective: The reason for the failure of most of the anti-HIV drugs are their poor pharmacokinetics, the poor risk to benefit ratio and the drug 
resistance. With the objective of developing newer pyrazole scaffolds for effective treatment of HIV, binding mode analysis of designing ligands with 
the HIV-1RT protein and prediction of key ADME and toxicity parameters of the compounds was in an area of interest.  
Methods: In this study, molecular docking studies and ADME-T studies were carried out in designing of some novel pyrazole analogs. The protein 
(PDB ID: 1RT2) was prepared using the Protein Preparation Wizard (Schrodinger Glide 5.0). ADME parameters calculated by QikProp 3.0v and 
toxicity of designed analogs checked by using two different online software’s namely Lazar and protox.  
Results: Most of the designed pyrazole analogs have good oral absorption as well as good binding affinity towards HIV-1 reverse transcriptase.  
Conclusion: Finally total 5 analogs (SGS-2, 3, 12, 13 and 14) from the 14 designed leads were found to be best on the basis of molecular docking and 
ADME-T studies. 
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The replication of the retrovirus takes place in two steps. First, the 
transcription of a single-stranded (+) RNA genome into a double-
stranded DNA and in the second step, an integration of these into the 
host genome [1, 2]. It is a complex process and requires the concerted 
function of both the DNA polymerase and the ribonuclease H. Thus, in 
the replication of HIV-1 reverse transcriptase play a pivotal role and is 
a primary target for antiviral drug development.  
The nonnucleoside reverse transcriptase inhibitors are a category of 
drugs that have been developed and approved by USFDA for the 
treatment of HIV-1 infection [2, 3]. The design and development of 
the first generation HIV-1 nonnucleoside reverse transcriptase 
inhibitors were failed owing to their inflexibility to interact with 
their specific binding pockets. Resistance exerted by the wild-type 
HIV-1 strains also were attributed to this fact. In addition to their 
high specificity to the binding pockets, high potency, and low 
cytotoxicity made the second-generation nonnucleoside reverse 
transcriptase inhibitors the drug of choice to treat the HIV infection. 
Examples include nevirapine, delavirdine, efavirenz, etravirine, and 
rilpivirine [4]. The structural flexibility of second-generation 
nonnucleoside reverse transcriptase inhibitors, etravirine, 
rilpivirine is to bind to the mutated nonnucleoside binding pocket 
thereby being more effective compared to older drugs [5]. However, 
the poor pharmacokinetics, unsatisfactory side effects and the rapid 
appearance of drug resistance of the these clinically approved anti-
HIV drugs compelled the medicinal chemist to develop novel 
nonnucleoside reverse transcriptase inhibitors or modify the 
existing nonnucleoside reverse transcriptase inhibitors [6-8].  
In addition, to the interactions with reverse transcriptase, there are 
certain features to be fulfilled by the drugs to interact and bind with 
nonnucleoside reverse transcriptase inhibitor receptors. To describe 
in brief, the designed analog has a ‘‘butterfly’’ with one ‘‘body’’ 
hydrophilic center (site A) and two hydrophobic ‘‘wings’’, mostly 
aryl moieties (wings B and C) [9, 10]. One of the “wings” of this 
butterfly is made of the π-electron-rich moiety (phenyl or allyl 
substituents) that interacts through π-π interactions with a 
hydrophobic pocket formed mainly by the side chains of aromatic 
amino acids (Tyr181, Tyr188, Phe227, Trp229 and Tyr318). The 
other wing is normally represented by a heteroaromatic ring 
bearing on one side a functional group capable of donating and/or 
accepting hydrogen bonds with the main chain of the Lys101 and 
Lys103. Finally, on the butterfly body, a hydrophobic portion fulfills 
a small pocket formed mainly by the side chains of Lys103, Val106 
and Val179. Inactivation of enzymes results from the complexation 
of the nonnucleoside binding pockets. This leads to changes in its 
own conformation. Thus, different chemical and structural features 
of the inhibitors and their side-chain flexibility make the bound 
nonnucleoside binding pockets to undergo different conformation 
changes. In addition, mutations of a few amino acids also cause a 
variation of the nonnucleoside binding pocket properties, which can 
decrease the affinity of most of the inhibitors [10, 11]. 
Pyrazole analogs have shown significant biological activities such as 
antipyretic, anti-inflammatory, analgesic, antimicrobial [12], anticancer 
[13], monoamine oxidative inhibitory [14] and various other activities. 
Recent reports revealed that a pyrazole analog lersivirine had been 
reported as a nonnucleoside reverse transcriptase inhibitor [15].  
During the design of a drug, a balance between pharmacokinetics, 
toxicology, and efficacy of the drugs are a main area of consideration. A 
recent report shows that just 12 % or fewer drugs are only being 
reaching into the market. Nowadays, a medicinal chemist can utilize 
the tools of Insilco design to reduce this failure rate by a proper prior 
prediction of properties of the drug candidate [16].  
Thus, the main objective of the current investigation is to find out 
the binding mode analysis of designed ligands with the HIV-1 
reverse transcriptase protein (PDB ID-1RT2) especially to analyse 
the amino acids present in the active binding site of reverse 
transcriptase, the type and number of binding interactions along 
with prediction of ADME parameters of the designed compounds. 
Further, the toxicity of designed analogs has also been performed by 
using two different online software’s namely lazar and protox. 
MATERIALS AND METHODS 
All computational analysis was performed on a Red Hat 5.0 Linux 
platform (Red Hook, NJ) running on a Dell Precision workstation 
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(Round Rock, TX) with an Intel Core 2 quad processor and 8 GB of 
RAM.  
ADME prediction 
The prediction of ADME (Absorption, Distribution, Metabolism, and 
Excretion) properties is considered to be a vital role in the build-up 
of new drug candidates. The ADME properties of the proposed 
analogs were generated by the Schrodinger’s Qik Prop. This 
provides ranges for comparing a molecule’s properties with those of 
95% of known drugs. It also evaluates the suitability of drugs based 
on Lipinski’s rule of five, which is essential to ensure drug like 
pharmacokinetics profile while using rational drug design. 
According to Lipinski’s rule of five, a molecule is said to be orally 
active when its molecular weight (MW) ˂ 500g/ Mol, calculated 
octanol/water partition coefficient (c LogP) ˂ 5, hydrogen bond 
donor (HBD) ˂  5, hydrogen bond acceptor (HBA) ˂ 10 and  the 
number of rotatable bonds ˂5 [17]. 
Docking study 
Protein structure preparation 
The X-ray crystal structures of HIV-1-RT protein, PDB ID: 1RT2 (fig. 
1) were obtained from the protein data bank (Research 




Fig. 1: X-ray crystal structures of HIV-1-RT protein bound with 
TNK-651 
 
The proteins were then prepared using the Protein Preparation 
Wizard (Schrodinger Glide 5.0) in which only chain A had been 
selected for the docking studies. Pre-processed bond orders were 
assigned, hydrogens were added, metals were treated, and water 
molecules were deleted. Heterostate for co-crystallized ligand was 
generated using Epik protonation state and optimization of H-
bonding of the protein side-chains were assigned using Prot Assign. 
The energy was minimized (Impref minimization) using RMSD 0.30 
converged by OPLS2005 force field utilities of Schrodinger’s Suite 
8.5. A radius of 10 A ° was selected for active site cavity during 
receptor grid generation. 
Ligand structure preparation 
All the ligands used in the docking study with glide were built within 
maestro by using build module of Schrodinger Inc. After clean up the 
structure energy minimization was performed followed by different 
conformers are generated by maestro tools. Partial atomic charges 
were computed using the OPLS_2005 force field. Finally, ligprep was 
prepared for the docking. 
Docking protocol and their validation 
All docking calculations were then performed using the ‘‘Extra 
precision’’ (XP) mode of Glide Program 5.0. A grid was generated 
with the center defined by the co-crystallized internal ligand of HIV-
1RT2. During the docking process, initially, Glide performed a 
complete systematic search of the conformational, orientation and 
positional space of the docked ligand and eliminated unwanted 
conformations using scoring followed by energy optimization. 
Finally, the conformations were further refined via Monte Carlo 
sampling of pose conformation. The most suitable method of 
evaluating the accuracy of a docking procedure is to determine how 
closely the lowest energy poses predicted by the scoring function 
resembles an experimental binding mode as determined by X-ray 
crystallography [18]. The reliability of the docking results was 
checked by comparing the docking scores obtained for the co-
crystallized inhibitor with its bound conformation. This was carried 
out by removing each non-nucleoside reverse transcriptase inhibitor 
from their active site and redocked into their binding pocket in the 
conformation found in the crystal structure. 
Toxicity studies of designed analogs 
The analogs which have shown a high binding affinity were selected 
and further subjected to toxicity predictions using two different 
software’s namely lazar, protox software. All of them have different 
parameters for determining the toxicity of compounds.  
Lazar 
Lazar is a modular framework which helps for the prediction of toxic 
properties based on functional group similarity with mutagenic or 
carcinogenic parameters by conducting a virtual assay test with 
Salmonella typhimurium and correlates the results with a standard 
which are preassigned in the software [19, 20]. Lazar is freely 
accessible from http://lazar.insilico.ch all the selected analogs 
structures (SGS-1 to SGS-14) have been submitted in lazar online 
web server as input data for predicting the toxicity of the 
compounds.  
Protox 
Computational toxicity studies are having an important role in the 
reduction of the number of animal experiments, time and cost. 
Protox is one of the suitable web servers to evaluate the similarity of 
compounds with known toxic things and toxic fragments. In 
addition, the web server gives the information about the possible 
binding affinity of drugs to the different toxicity targets by using 
various protein–ligand pharmacophore based models [21]. All the 
selected analogs 2D structures (SGS-1 to SGS-14) have been drawn 
and submitted for prediction (http://tox. charite. de/tox). 
RESULTS AND DISCUSSION 
Reverse transcriptase enzyme which plays a crucial and a 
multifunctional character in the replication of the human 
immunodeficiency virus (HIV) and thus exhibits an attractive target 
for the development of HIV drugs [18, 19]. Even though, there are a 
few successful drugs developed the booming prevalence of 
resistance to these drug candidates and a pulse of their adverse 
effects made it essential to develop antiviral agents which are active 
against mutant HIV strains. Thus, in the present investigation, we 
have designed various pyrazole analogs towards HIV-1 reverse 
transcriptase they were subjected to molecular docking studies on 
crystal structures of HIV-1RT2 complexed with ligand TNK-651. 
The Qik Prop results of the current investigation have indicated that 
all the designed molecules are obeying Lipinski rule of five, it’s 
proven its drug-likeness character (table 1). Predicted 
physicochemical characteristics expressed by various descriptors 
like the optimum value of rotatable bonds, polar surface area, etc. 
assures the oral bioavailability of the designed compounds. 
The results of intestinal absorption of the designed molecules 
predicted by Caco-2 cell (QPP Caco) and human serum albumin 
binding mode predicted by QP log khsa, blood/brain partition 
coefficient QP log BB, cell permeability of the blood brain barrier 
which mimic MDCK cells (QPPMDCK) values also denotes that most 
of the designed analogs are coming to the prescribed range (table 2). 
The cell permeability of these analogs also good agreement with 
their oral absorption rate. Cell permeability, in turn, depends on the 
partition coefficient and water solubility a compound. The designed 
analogs (SGS-2,3,6,8,12,13,14) have shown octanol and water (log 
Po/w<5) and analogs (SGS-2,3,5,7,8,12,13,14) have solubility 
(QPlogS: -6.5 to 0.5) coefficient values in an acceptable range. 
Further, log BB data shows that all the designed analogs properties 
in the acceptable range, which indicates drug-like characteristics of 
designed analogs (table 2). 
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Rule of five 
SGS-1 m-Cl Cl 387.26 0 5.0 5.11 62.64 5 1 
SGS-2 p-NO Cl 2 397.81 0 6.5 3.60 97.57 6 0 
SGS-3 p-OCH Cl 3 382.84 0 5.75 4.66 70.94 6 0 
SGS-4 3,4 Cl Cl 421.70 0 5.0 5.55 62.64 5 1 
SGS-5 2,4,5 Cl Cl 456.15 0 5.0 5.9 61.47 5 1 
SGS-6 2,4-NO Br 2 487.26 0 8.0 2.79 130.2 7 0 
SGS-7 m-Cl Br 431.71 0 5.0 5.23 62.64 5 1 
SGS-8 p-NO Br 2 442.26 0 6.5 3.7 97.57 6 0 
SGS-9 αnaphthylamine Cl 402.87 0 5.0 5.59 62.62 5 1 
SGS-10 αnaphthylamine Br 447.32 0 5.0 5.70 62.62 5 1 





















SGS-14 p-OCH CH3 362.43 3 0 5.75 4.48 70.93 6 0 
Mol. Wt-molecular weight; donor HB-hydrogen bond donor; acceptor HB-hydrogen bond acceptor; QP log P o/w-partition coefficient; PSA A °-polar 
surface area; # rotor-rotatable bonds,rule of five-Number of Lipinsky rule violation 
 
Table 2: ADME-parameters calculated from QikProp 
Compound 
Code 






















SGS-1 m-Cl Cl -8.70  100 2621.6 -0.03  0.52 -6.41 8541.70 
SGS-2 p-NO Cl 2 -8.82  95.9 472.5 -1.10  0.09 -5.21 543.33 
SGS-3 p-OCH Cl 3 -8.80  100 2620.9 -0.26  0.36 -5.75 3461.23 
SGS-4 3,4 Cl Cl -8.45  100 2621.6 0.09  0.63 -7.05 10000.0 
SGS-5 2,4,5 Cl Cl -8.26  100 2629.1 -0.30  0.39 -5.00 1365.8 
SGS-6 2,4-NO Br 2 -6.95  100 2559.4 0.22  0.72 -7.68 10000.0 
SGS-7 m-Cl Br -7.86  100 2621.5 -1.10  0.13 -6.59 599.14 
SGS-8 p-NO Br 2 -7.53  96.5 472.5 -1.10  0.13 -5.38 3574.6 
SGS-9 αnaphthyl 
amine 
Cl -7.68  100 2621.5 -0.22  0.79 -6.96 3492.03 
SGS-10 αnaphthyl 
amine 
Br -7.89  100 2621.4 -0.21  0.83 -6.96 3492.03 
SGS-11 3,4 Cl Br -7.45  100 2621.6 0.11  0.67 -7.23 10000.0 
SGS-12 p-OCH Br 3 -8.77  100 2620.8 -0.25  0.40 -5.92 3816.69 
SGS-13 m-NO Cl 2 -8.92  100 474.0 -1.10  0.09 -5.20 545.17 
SGS-14 p-OCH CH3 -8.72 3  100 2621.1 -0.44  0.41 -5.59 1401.82 
Standard TNK-651  -13.27       
 
Data indicate the descriptor calculated from Quikprop. Range/ 
recommended values calculated for 95% known drugs. % HOA-
percentage human oral absorption; QPP Caco-predicted Caco-2 cell 
permeability; QP log Khsa-predicted blood/brain partition coefficient; 
QP log Khsa-predicted human serum albumin; QPP MDCK-predicted 
MDCK permeability; QP log S-predicted aqueous solubility. 
The accurate prediction of protein–ligand interaction geometries is 
essential for the success of virtual screening approaches in 
structure-based drug design. It requires docking tools that are able 
to generate suitable conformations of a ligand within a protein 
binding site and reliable, energetic evaluation indicating the quality 
of the interaction. The designed pyrazole analogs with the highest 
docking score (SGS-13) have shown a good binding affinity towards 
the non-nucleotide binding pocket site of reverse transcriptase 
enzyme. The dock score of designed analogs and standard drug TNK-
651 was summarized in table 2.  
To develop more efficient HIV-1 reverse transcription inhibitors, 
especially active against mutant strains, we further analyzed the 
various interactions [(hydrogen bonding (backbone and side chain), 
π-π interaction of highest docking score analogs towards with amino 
acids of the binding pocket of HIV-1 reverse transcriptase. 
Compound SGS-13 had interaction with protein (PDB: 1RT2) 
through π-π stacking (Phe 227) and hydrophobic interactions with 
Val 106, Pro 226, Pro 225,Tyr 318,Leu 234,Trp 229,Tyr 188,Tyr 181, 
Leu 100, Pro 236 (fig. 2). 
The binding pattern of Standard drug TNK 651 also interact with 
protein (PDB: 1RT2) through π-π stacking (Trp 229) and 
hydrophobic interactions (Pro 236, Tyr 181, Pro 95, Pro 225, Val 
106, Pro 226, Leu 234, Tyr 318, Leu 100, Val 179, Ile 180, Val 189, 
Tyr 188 and Phe 227) and hydrogen bond (back bond) interaction 
with Lys 101 (fig. 3). 
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Fig. 2: Ligand interaction pattern of selected analog (SGS-13) 
into the active site NNBP of 1RT2 
 
The toxicity of selected compounds has been predicted by using 
lazar and protox. The lazar results have predicted that the designed 
analogs (SGS-1 to SGS-6, SGS-10, SGS-13) is non-carcinogenic in 
mouse and rat model. The compound SGS-7 and SGS-8 were 
predicted to be carcinogenic towards mouse model and rat model, 
while compounds SGS-9, SGS-11, SGS-12 and SGS-14 has been 
predicted to be non-carcinogenic towards rat but carcinogenic 
towards mouse model. The all selected analogs have predicted their 
mutagenicity towards S. typhimurium. Compound SGS-1 to SGS-7, 
SGS-11 to SGS-14 was found to be inactive, but compound SGS-8 to 




Fig. 3: Redocked conformer of TNK-651 into the active site 
NNBP of 1RT2 
 
Table 3: Toxicity prediction of selected analogs 
Compound code Mutagenicity (lazar) 
(S. typhimurium) 
Carcinogenicity (lazar) 




50 predicted toxicity class 
SGS-1 inactive inactive inactive 629 mg/kg CLASS 4 
SGS-2 inactive inactive inactive 5000 mg/kg CLASS 5 
SGS-3 inactive inactive inactive 1000 mg/kg CLASS 4 
SGS-4 inactive inactive inactive 1000 mg/kg CLASS 4 
SGS-5 inactive inactive inactive 629 mg/kg CLASS 4 
SGS-6 inactive inactive inactive 629 mg/kg CLASS 4 
SGS-7 inactive active active 629 mg/kg CLASS 4 
SGS-8 active active active 629 mg/kg CLASS 4 
SGS-9 active inactive active 629 mg/kg CLASS 4 
SGS-10 active inactive inactive 629 mg/kg CLASS 4 
SGS-11 inactive inactive active 629 mg/kg CLASS 4 
SGS-12 inactive inactive active 629 mg/kg CLASS 4 
SGS-13 inactive inactive inactive 629 mg/kg CLASS 4 
SGS-14 inactive inactive active 1000 mg/kg CLASS 4 
 
LD50 is defined as the dose at which 50% of the tested animal die. 
LD50 data is helping to determine the effective dose of a compound 
and gives the level of compound's acute toxicity. The acute toxicity 
data predicted by protox showed that all the selected compounds 
had high LD50
CONCLUSION  
 values that falls under the toxicity class 4 (SGS-1, SGS-
3 to SGS-14) and toxicity class 5 (SGS-2) according to the GHS, 
United Nations guidelines (UN GHS, 2005) [20]. From this findings, it 
was revealed that in future, these designed pyrazole analogs may 
exhibit better effective inhibition of HIV-1 wild type the most drug-
resistant mutant strains.  
A good binding affinity towards HIV-1 reverse transcriptase and a 
better predicted oral absorption pattern were observed in the case 
of all the designed pyrazole analogs. To highlight, a total of 5 analogs 
(SGS-2, 3, 12, 13 and 14) from the 14 designed leads, were found to 
be best, on the basis of their molecular docking and ADME-T studies. 
These analogs may be effective in the inhibition of HIV-1 reverse 
transcripters strains. Thus, these pyrazole compounds can be made 
into unique novel anti-HIV drugs.  
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